

Merck Pipeline

3Q2026 Reflecting Pipeline to **5-Aug-2026**

5-Aug-2026



Lead-in language

The chart below reflects the company's research pipeline as of **5-Aug-2026**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics generally are given MK-number designations and vaccine candidates generally are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer, immunology and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.

Merck pipeline as of 5-Aug-2026

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Bladder Cervical Endometrial Esophageal Gastric HCC Melanoma NSCLC Ovarian Pancreatic Prostate patritumab deruxtecan MK-1022¹	Cancer Heme MK-1045	Solid Tumors calderasib MK-1084¹	Alzheimer's Disease MK-2214	Cancer Biliary Bladder Breast Cervical Endometrial HCC HNSCC Melanoma NSCLC Ovarian Pancreatic Solid Tumors ifinatamab deruxtecan MK-2400¹	Cancer Biliary Esophageal Neoplasm Malignant sacituzumab tirumotecan MK-2870¹
Cancer Bladder MK-3120	Cancer Prostate KEYTRUDA® MK-3475	Cancer Heme (US) KEYTRUDA QLEX™ MK-3475A	PH-COPD frespaciguat MK-5475	Cancer Breast Endometrial Ovarian opevesostat MK-5684	COPD ensifentrine (+) glycopyrrolate MK-5884A

Merck pipeline as of 5-Aug-2026

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Cervical Endometrial Gastric NSCLC SCLC raludotatug deruxtecan MK-5909¹	MASH efinopegdutide MK-6024	Cancer SCLC gocatamig MK-6070¹	Cancer Breast WELIREG™ MK-6482	Immunology Axial Spondyloarthritis Hidradenitis Suppurativa Psoriatic Arthritis Rheumatoid Arthritis Systemic Sclerosis tulisokibart MK-7240	Atherosclerosis MK-7262
Pulmonary Hypertension due to Left Heart Disease WINREVAIR™ MK-7962	HIV-1 Infection islatravir (+) ulonivirine MK-8591B	Immunology Ulcerative Colitis MK-8690	Cancer Bladder RCC intismeran autogene V940¹		

Merck pipeline as of 5-Aug-2026

1. Being developed in a collaboration.
2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials.
3. LAGEVRIO™ is available in the U.S under Emergency Use Authorization, which will terminate effective June 29, 2027.
4. Program is in Phase 2/3 studies.

► Moved forward since last pipeline update.

Phase 3	Phase 3	Phase 3	Phase 3	Phase 3	Phase 3
Cancer Breast patritumab deruxtecan MK-1022 ¹	Cancer Heme nemtabrutinib MK-1026	Cancer CRC NSCLC calderasib MK-1084 ¹	Influenza MK-1406	Cancer Heme zilovertamab vedotin MK-2140	Cancer Esophageal Prostate SCLC (EU) ifinatamab deruxtecan MK-2400 ¹
Cancer Bladder Breast Cervical Endometrial Gastric NSCLC Ovarian sacituzumab tirumotecan MK-2870 ¹	Diabetic Macular Edema remigromig MK-3000 ⁴	Cancer SCLC KEYTRUDA® MK-3475	Cancer Myeloproliferative Disorders bomedemstat MK-3543	COVID-19 LAGEVRIO® MK-4482 ^{1,3} (US)	Cancer Prostate opevesostat MK-5684
Cancer Ovarian raludotatug deruxtecan MK-5909 ¹	Immunology Crohn's Disease Ulcerative Colitis tulisokibart MK-7240	Cancer NSCLC SCLC LYNPARZA® MK-7339 ¹	HIV-1 PrEP alimatravir MK-8527	HIV-1 Infection islatravir (+) lenacapavir MK-8591D ^{1,2}	Neovascular Age-Related Macular Degeneration MK-8748 ⁴
Dengue Fever Virus Vaccine V181	Cancer Melanoma NSCLC intismeran autogene V940 ¹				

Merck pipeline as of 5-Aug-2026

1. Being developed in a collaboration.
2. Under review for combination use with KEYTRUDA®.
3. Under review in Japan for Lenvima, used in combination with WELIREG®.

► Moved forward since last pipeline update.

New Molecular Entities Under Review	New Molecular Entities Under Review	Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review
Primary Hypercholesterolemia or Mixed Dyslipidemia LIPFENDRA® MK-0616 (EU)	Previously Treated Extensive-Stage SCLC ifinatumab deruxtecan MK-2400¹ (US)	Cisplatin Eligible Muscle Invasive Bladder Cancer (KNB15) KEYTRUDA® MK-3475 (EU, JPN)	Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) KEYTRUDA® MK-3475 (JPN)	Newly Diagnosed High-Risk Endometrial Cancer (KNB21) KEYTRUDA® MK-3475 (EU)	Platinum-Resistant Recurrent Ovarian Cancer (KNB96) KEYTRUDA® MK-3475 (JPN)
HIV-1 Infection doravirine (+) islatravir MK-8591A IDVYNISO™ (EU)		Clear Cell Renal Cell Carcinoma Following Nephrectomy (LITESPARK-022) WELIREG® MK-6482² (EU)	Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-011) WELIREG® MK-6482^{1,3} (US, EU, JPN)	Pulmonary Arterial Hypertension (HYPERION) WINREVAIR™ MK-7962 (US)	

Merck pipeline as of 5-Aug-2026

1. Approvals obtained within the last 3 months.
 2. MK-3475A to be marketed under the trade name KEYTRUDA SC in the EU.
 3. For combination use with KEYTRUDA® or KEYTRUDA QLEX™.
- Moved forward since last pipeline update.

New Molecular Entities Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹
Hypercholesterolemia LIPFENDRA® MK-0616 (US)	Cisplatin Eligible Muscle Invasive Bladder Cancer (KNB15) KEYTRUDA® MK-3475 (US)	Cisplatin Eligible Muscle Invasive Bladder Cancer (KNB15) KEYTRUDA QLEX™ MK-3475A (US)	Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) KEYTRUDA® MK-3475 (EU)	Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) KEYTRUDA QLEX™ MK-3475A² (EU)
Respiratory Syncytial Virus ENFLONSIA™ MK-1654 (JPN, CHN)	First Line Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (KND19) KEYTRUDA® MK-3475 (US)	First Line Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (KND19) KEYTRUDA QLEX™ MK-3475A (US)	Platinum-Resistant Recurrent Ovarian Cancer (KNB96) KEYTRUDA® MK-3475 (CHN)	Clear Cell Renal Cell Carcinoma Following Nephrectomy (LITESPARK-022) WELIREG® MK-6482³ (US)
	Pulmonary Arterial Hypertension (HYPERION) WINREVAIR™ MK-7962 (EU)	Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease CAPVAXIVE™ V116 (STRIDE-13) (US)		

Forward-looking statement

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No duty to update

The information contained in the presentation set forth below was current as of **5-Aug-2026**. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after **5-Aug-2026**.

The chart reflects the Merck research pipeline as of **5-Aug-2026**.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.